- Home
- NHS vs RAPT Comparison
NHS vs RAPT Comparison
Compare NHS & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- RAPT
- Stock Information
- Founded
- NHS 2003
- RAPT 2015
- Country
- NHS United States
- RAPT United States
- Employees
- NHS N/A
- RAPT N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- NHS Finance
- RAPT Health Care
- Exchange
- NHS Nasdaq
- RAPT Nasdaq
- Market Cap
- NHS 229.5M
- RAPT 194.2M
- IPO Year
- NHS N/A
- RAPT 2019
- Fundamental
- Price
- NHS $7.65
- RAPT $18.00
- Analyst Decision
- NHS
- RAPT Buy
- Analyst Count
- NHS 0
- RAPT 5
- Target Price
- NHS N/A
- RAPT $33.60
- AVG Volume (30 Days)
- NHS 111.8K
- RAPT 89.6K
- Earning Date
- NHS 01-01-0001
- RAPT 11-11-2025
- Dividend Yield
- NHS 13.44%
- RAPT N/A
- EPS Growth
- NHS N/A
- RAPT N/A
- EPS
- NHS N/A
- RAPT N/A
- Revenue
- NHS N/A
- RAPT N/A
- Revenue This Year
- NHS N/A
- RAPT N/A
- Revenue Next Year
- NHS N/A
- RAPT N/A
- P/E Ratio
- NHS N/A
- RAPT N/A
- Revenue Growth
- NHS N/A
- RAPT N/A
- 52 Week Low
- NHS $6.95
- RAPT $5.67
- 52 Week High
- NHS $9.17
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- NHS 66.40
- RAPT 81.43
- Support Level
- NHS $7.56
- RAPT $11.19
- Resistance Level
- NHS $7.68
- RAPT $13.66
- Average True Range (ATR)
- NHS 0.06
- RAPT 1.04
- MACD
- NHS 0.02
- RAPT 0.58
- Stochastic Oscillator
- NHS 85.42
- RAPT 96.62
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.